Removing T-cell Epitopes with Computational Protein Design

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2014 May 21

PMID 24843166

Citations 60

Authors

Chris King

Esteban N Garza

Ronit Mazor

Jonathan L Linehan

Ira Pastan

Marion Pepper

David Baker

Affiliations

Soon will be listed here.

Abstract

Immune responses can make protein therapeutics ineffective or even dangerous. We describe a general computational protein design method for reducing immunogenicity by eliminating known and predicted T-cell epitopes and maximizing the content of human peptide sequences without disrupting protein structure and function. We show that the method recapitulates previous experimental results on immunogenicity reduction, and we use it to disrupt T-cell epitopes in GFP and Pseudomonas exotoxin A without disrupting function.

Citing Articles

Leveraging mRNA technology for antigen based immuno-oncology therapies.

Floudas C, Sarkizova S, Ceccarelli M, Zheng W J Immunother Cancer. 2025; 13(1).

PMID: 39848687 PMC: 11784169. DOI: 10.1136/jitc-2024-010569.

Rational engineering of minimally immunogenic nucleases for gene therapy.

Raghavan R, Friedrich M, King I, Vo S, Strebinger D, Lash B Nat Commun. 2025; 16(1):105.

PMID: 39747875 PMC: 11696374. DOI: 10.1038/s41467-024-55522-1.

A mathematical model simulating the adaptive immune response in various vaccines and vaccination strategies.

Xu Z, Song J, Zhang H, Wei Z, Wei D, Yang G Sci Rep. 2024; 14(1):23995.

PMID: 39402093 PMC: 11473516. DOI: 10.1038/s41598-024-74221-x.

A review and outlook on expression of animal proteins in plants.

Tuse D, McNulty M, McDonald K, Buchman L Front Plant Sci. 2024; 15:1426239.

PMID: 39239203 PMC: 11374769. DOI: 10.3389/fpls.2024.1426239.

Robust genome and cell engineering via in vitro and in situ circularized RNAs.

Tong M, Palmer N, Dailamy A, Kumar A, Khaliq H, Han S Nat Biomed Eng. 2024; 9(1):109-126.

PMID: 39187662 DOI: 10.1038/s41551-024-01245-z.

References

Nielsen M, Lund O, Buus S, Lundegaard C . MHC class II epitope predictive algorithms. Immunology. 2010; 130(3):319-28. PMC: 2913211. DOI: 10.1111/j.1365-2567.2010.03268.x. View

Parker A, Zheng W, Griswold K, Bailey-Kellogg C . Optimization algorithms for functional deimmunization of therapeutic proteins. BMC Bioinformatics. 2010; 11:180. PMC: 2873530. DOI: 10.1186/1471-2105-11-180. View

Persons D, Allay J, Riberdy J, Wersto R, Donahue R, Sorrentino B . Use of the green fluorescent protein as a marker to identify and track genetically modified hematopoietic cells. Nat Med. 1998; 4(10):1201-5. DOI: 10.1038/2704. View

Vita R, Zarebski L, Greenbaum J, Emami H, Hoof I, Salimi N . The immune epitope database 2.0. Nucleic Acids Res. 2009; 38(Database issue):D854-62. PMC: 2808938. DOI: 10.1093/nar/gkp1004. View

Hassan R, Bullock S, Premkumar A, Kreitman R, Kindler H, Willingham M . Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007; 13(17):5144-9. DOI: 10.1158/1078-0432.CCR-07-0869. View

Nivon L, Bjelic S, King C, Baker D . Automating human intuition for protein design. Proteins. 2013; 82(5):858-66. DOI: 10.1002/prot.24463. View

Tangri S, Mothe B, Eisenbraun J, Sidney J, Southwood S, Briggs K . Rationally engineered therapeutic proteins with reduced immunogenicity. J Immunol. 2005; 174(6):3187-96. DOI: 10.4049/jimmunol.174.6.3187. View

Yanover C, Bradley P . Large-scale characterization of peptide-MHC binding landscapes with structural simulations. Proc Natl Acad Sci U S A. 2011; 108(17):6981-6. PMC: 3084072. DOI: 10.1073/pnas.1018165108. View

Choi Y, Griswold K, Bailey-Kellogg C . Structure-based redesign of proteins for minimal T-cell epitope content. J Comput Chem. 2013; 34(10):879-91. PMC: 3763725. DOI: 10.1002/jcc.23213. View

10.

Parker A, Griswold K, Bailey-Kellogg C . Optimization of therapeutic proteins to delete T-cell epitopes while maintaining beneficial residue interactions. J Bioinform Comput Biol. 2011; 9(2):207-29. DOI: 10.1142/s0219720011005471. View

11.

Pastan I, Beers R, Bera T . Recombinant immunotoxins in the treatment of cancer. Methods Mol Biol. 2004; 248:503-18. DOI: 10.1385/1-59259-666-5:503. View

12.

Southwood S, Sidney J, Kondo A, del Guercio M, Appella E, Hoffman S . Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol. 1998; 160(7):3363-73. View

13.

Hammer J, Valsasnini P, Tolba K, Bolin D, Higelin J, TAKACS B . Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell. 1993; 74(1):197-203. DOI: 10.1016/0092-8674(93)90306-b. View

14.

Pedelacq J, Cabantous S, Tran T, Terwilliger T, Waldo G . Engineering and characterization of a superfolder green fluorescent protein. Nat Biotechnol. 2005; 24(1):79-88. DOI: 10.1038/nbt1172. View

15.

Mazor R, Vassall A, Eberle J, Beers R, Weldon J, Venzon D . Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A. Proc Natl Acad Sci U S A. 2012; 109(51):E3597-603. PMC: 3529021. DOI: 10.1073/pnas.1218138109. View

16.

Baker M, Carr F . Pre-clinical considerations in the assessment of immunogenicity for protein therapeutics. Curr Drug Saf. 2010; 5(4):308-13. DOI: 10.2174/157488610792246000. View

17.

Moon J, Chu H, Pepper M, McSorley S, Jameson S, Kedl R . Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity. 2007; 27(2):203-13. PMC: 2200089. DOI: 10.1016/j.immuni.2007.07.007. View

18.

Kreitman R, Tallman M, Robak T, Coutre S, Wilson W, Stetler-Stevenson M . Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012; 30(15):1822-8. PMC: 3383181. DOI: 10.1200/JCO.2011.38.1756. View

19.

Cantor J, Yoo T, Dixit A, Iverson B, Forsthuber T, Georgiou G . Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc Natl Acad Sci U S A. 2011; 108(4):1272-7. PMC: 3029727. DOI: 10.1073/pnas.1014739108. View

20.

Singh H, Raghava G . ProPred: prediction of HLA-DR binding sites. Bioinformatics. 2001; 17(12):1236-7. DOI: 10.1093/bioinformatics/17.12.1236. View